Gsk (GSK) Net Income towards Common Stockholders Growth (5y) (2014 - 2026)

Gsk (GSK) Net Income towards Common Stockholders Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 9.62%
Dec 31, 2025 -35.52%
Sep 30, 2025 -10.93%
Jun 30, 2025 -7.29%
Mar 31, 2025 0.39%
Dec 31, 2024 11.27%
Sep 30, 2024 -15.32%
Jun 30, 2024 3.61%
Mar 31, 2024 4.19%
Dec 31, 2023 19.84%
Sep 30, 2023 0.07%
Jun 30, 2023 27.60%
Mar 31, 2023 18.85%
Dec 31, 2022 92.16%
Sep 30, 2022 51.73%
Jun 30, 2022 45.80%
Mar 31, 2022 13.29%
Dec 31, 2021 25.87%
Sep 30, 2021 8.68%
Jun 30, 2021 38.63%